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DObjective: Clinical models incompletely predict the outcomes after coronary artery bypass grafting. Novel
molecular technologies can identify biomarkers to improve risk stratification. We examined whether metabolic
profiles can predict adverse events in patients undergoing coronary artery bypass grafting.
Methods: The study population comprised 478 subjects from the CATHGEN biorepository of patients referred
for cardiac catheterization who underwent coronary artery bypass grafting after enrollment. Targeted mass
spectrometry-based profiling of 69 metabolites was performed in frozen, fasting plasma samples collected
before surgery. Principal components analysis and Cox proportional hazards regression modeling were used
to assess the relation between the metabolite factor levels and a composite outcome of postcoronary artery
bypass grafting myocardial infarction, the need for percutaneous coronary intervention, repeat coronary artery
bypass grafting, and death.
Results:During amean follow-up period of 4.3 2.4 years, 126 subjects (26.4%) experienced an adverse event.
Three principal components analysis-derived factors were significantly associated with an adverse outcome on
univariate analysis: short-chain dicarboxylacylcarnitines (factor 2, P¼ .001); ketone-related metabolites (factor
5, P¼ .02); and short-chain acylcarnitines (factor 6, P¼ .004). These 3 factors remained independently predic-
tive of an adverse outcome after multivariate adjustment: factor 2 (adjusted hazard ratio, 1.23; 95% confidence
interval, 1.10–1.38; P<.001), factor 5 (odds ratio, 1.17; 95% confidence interval, 1.01–1.37; P ¼ .04), and
factor 6 (odds ratio, 1.14; 95% confidence interval, 1.02–1.27; P ¼ .03).
Conclusions: Metabolic profiles are independently associated with adverse outcomes after coronary artery
bypass grafting. These profiles might represent novel biomarkers of risk that can augment existing tools for
risk stratification of coronary artery bypass grafting patients and might elucidate novel biochemical pathways
that mediate risk. (J Thorac Cardiovasc Surg 2012;143:873-8)Coronary heart disease remains the leading cause of death in
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to 10% of patients undergoing CABG require a subsequent
medical or surgical revascularization procedure within 3
years after surgery.1 Repeat CABG occurs in 11% of
patients by 10 years after the initial CABG.2 Furthermore,
14% to 36% of patients will have a new postoperativemyo-
cardial infarction (MI) within 10 years after their index
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DHowever, clinical models incompletely predict the risk of
adverse events after CABG. For example, the European
System for Cardiac Operative Risk Evaluation (Euro-
SCORE) model has a c-statistic of 0.79 and others have
a similar model fit.5 Furthermore, most currently available
risk models predict the perioperative risk but do not de-
scribe longer term risk. Thus, a gap remains in our risk pre-
diction models for adverse events after CABG. A better
understanding of risk could lead to alternate and/or adjunc-
tive perioperative strategies or the use of alternative initial
revascularization strategies to improve the outcomes of
patients at high risk of adverse events after CABG. Meta-
bolic profiling, the systematic study of the small molecule
byproducts of cellular metabolism, has been used to identify
novel cardiovascular biomarkers to improve risk stratifica-
tion and better understand the mechanisms of several
disease processes.6 In 1 recent study from our group, a clus-
ter of small-medium chain dicarboxylated acylcarnitine
metabolites was predictive of imminent cardiovascular
events (death/MI).7 We hypothesized that targeted meta-
bolic profiling would identify novel biomarkers of the risk
of adverse events after CABG and potentially provide a bet-
ter understanding of the disease pathophysiology.
METHODS
Study Population
The study population was selected from patients enrolled in the CATH-
GEN biorepository of more than 9000 subjects at Duke University Medical
Center, a biorepository of clinical and follow-up data and blood samples
collected from patients presenting for cardiac catheterization. Details of
the biorepository have been previously published.8 In brief, fasting blood
samples were collected in ethylenediamine-tetra-acetic acid tubes using
an arterial sheath at cardiac catheterization, before the administration of
supplemental heparin (if given). The blood tubes were then chilled to
4C, centrifuged within 30 minutes of collection, separated into aliquots,
and frozen at 80C. The demographics, medical history, angiographic
data, and longitudinal follow-up for the CATHGEN patients were collected
through the Duke Databank for Cardiovascular Disease, which has
archived this information for all patients undergoing cardiac procedures
at the Duke University Medical Center since 1969. The follow-up data
include annual determination of mortality, MI, hospitalizations, and coro-
nary revascularization procedures. Vital status is confirmed through the
National Death Index and Social Security Death Index.
Metabolic profiling had been performed on 3899 unique subjects from
December 2006 to March 2010.7,8 For the present study, we selected
all subjects with metabolic profiling who underwent CABG at any
point after their index CATHGEN cardiac catheterization. The Duke
University institutional review board approved the CATHGEN
biorepository and the present substudy. Before the collection of blood874 The Journal of Thoracic and Cardiovascular Surgsamples, all study subjects provided written informed consent to
participate.
Laboratory Methods
The levels of 45 acylcarnitines, 15 amino acids, ketones, b-hydroxybu-
tyrate, and total free fatty acids were quantitatively determined from fro-
zen, fasting plasma samples using previously reported methods with
known coefficients of variation.7,9,10 The laboratory (Sarah W. Stedman
Nutrition and Metabolism metabolomics core laboratory) was kept
unaware of the event status, and the samples were randomly numbered
with respect to event status. Acylcarnitines and amino acids were
profiled using a mass spectrometry-based protocol.9,11 The proteins were
first removed by precipitation with methanol. Aliquots of supernatants
were then dried and esterified with hot, acidic methanol (acylcarnitines)
or n-butanol (amino acids). The analysis was done by tandem mass
spectroscopy with a Quattro Micro instrument (Waters, Milford, Mass).
Quantification of the ‘‘targeted’’ intermediary metabolites was facilitated
by the addition of mixtures of known quantities of stable-isotope internal
standards, as previously described.7,10,12
Statistical Analysis
The primary endpoint of the present study was occurrence of any event
at any point after CABG from within a composite adverse event, defined as
incident percutaneous coronary intervention, MI, repeat CABG, and death.
Principal components analysis was used, given the co-linearity of the
metabolites, to reduce the burden of adjustment for multiple comparisons.
Metabolites with more than 25% of the values equaling 0 (less than the
lower limits of quantification) were not analyzed (C6 and C7-DC acylcar-
nitines). Varimax rotation was used to produce identifiable factors. Factors
with an eigenvalue of 1 or more were retained according to the commonly
used Kaiser criterion.13 Metabolites with a factor load of 0.4 or more were
reported as constituting a given factor. Scoring coefficients were con-
structed and used to calculate factor scores for each individual (weighted
sum of the standardized metabolites within that factor, weighted on the
factor loading for each metabolite).
Cox proportional hazard regression modeling was used to assess the
association of factor levels with the interval to the first occurrence of any
component of the composite of MI, percutaneous coronary intervention,
repeat CABG, or death after the index CABG. Both univariate and multi-
variate models, adjusted for age, gender, race, dyslipidemia, diabetes, renal
disease, smoking, body mass index, baseline ejection fraction, number of
diseased coronary vessels at cardiac catheterization, and preprocedural
heparin use at sample collection, were performed. The multivariate models
also were adjusted for all factors significant on the univariate analyses
(P<.05). Clinical variables with P<.10 were retained in the final model.
For these time-to-event analyses, the day of CABG was considered the
baseline time zero. Kaplan-Meier curves, adjusted for all variables retained
in the final model, were constructed to visualize the relation of those factors
significantly associated with the composite event. The factor levels were
divided into tertiles for visualization purposes.
Statistical analysis was performed by 3 of us (D.M.C., A.A.S., and
S.H.S.) using SAS version 9.1, (SAS Institute, Cary, NC).RESULTS
Of 478 subjects who had metabolic profiling of baseline
samples collected at cardiac catheterization and subse-
quently underwent CABG, 126 (26.4%) experienced the
composite clinical endpoint after CABG during a mean
follow-up time of 4.3  2.4 years after CABG. Of the
126 patients, 19 (4.0%) experienced MI, 28 (5.9%) under-
went percutaneous coronary intervention, 4 (0.8%)ery c April 2012
TABLE 1. Baseline characteristics of study population
Characteristic Overall (n ¼ 478) No event subjects (n ¼ 352) Event subjects (n ¼ 126) P value
Age (y) 61  11 61  11 62  12 .33
Gender (% female) 159 (33) 111 (32) 48 (38) .18
Race (% white) 355 (74) 263 (75) 92 (73) .71
Diabetes 170 (36) 114 (32) 56 (44) .02
Dyslipidemia 309 (65) 227 (65) 82 (65) .91
Renal disease 12 (3) 5 (1) 7 (6) .02
Current smoker 262 (55) 188 (53) 74 (58) .30
BMI (kg/m2) 30  7 30  6 30  7 .69
Ejection fraction (%) 54  14 55  14 52  15 .03
Diseased coronary vessels (n) 2.3  0.8 2.3  0.8 2.5  0.8 .02
Preprocedure heparin use 116 (24) 77 (22) 39 (31) .05
Data presented as mean  standard deviation or numbers, with percentages in parentheses. BMI, Body mass index.
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Dunderwent repeat CABG, and 75 (15.7%) died (first
events). The median interval from enrollment in the
CATHGEN cardiac catheterization study to CABG was 4
days (interquartile range, 2–49). The baseline characteris-
tics of the study population according to event or no event
during follow-up are listed in Table 1.
The principal components analysis identified 12 meta-
bolic factors (Table 2), residing in biologically plausible
clusters, as previously reported.7,12,14 On univariate time-
to-event analyses, the levels of several factors were signifi-
cantly associated with the interval to the composite event
(Table 3). These included factor 2, consisting of short-
chain dicarboxylacylcarnitines (hazard ratio [HR], 1.19;
95% confidence interval [CI], 1.07–1.33; P ¼ .001); factor
5, consisting of ketone-related metabolites (HR, 1.21; 95%
CI, 1.04–1.41; P ¼ .02); and factor 6, consisting of short-TABLE 2. Principal components analysis
Factor Term Ind
1 Medium-chain acylcarnitines C8, C10, C10:1, C10-
C14:1-OH/C12:1-D
C16:2, C18:1-OH/C
2 Short-chain dicarboxylacylcarnitines Ci4-DC/C4-DC, C5-D
C8:1-DC, C10:1, C
C12-OH/C10-DC, c
3 Long-chain dicarboxylacylcarnitines C12-OH/C10-DC, C1
C18-OH/C16-DC, C
C20:1-OH/C18:1-D
4 Long-chain acylcarnitines C16, C16:1-OH/C14:1
5 Ketone-related Ketones, Hbut, C4-OH
6 Short-chain acylcarnitines C2, C3, C4/Ci4 C5s
7 Branched-chain amino acids Leucine/isoleucine, va
8 Urea cycle amino acids Methionine, serine, hi
9 Amino acids Glycine, histidine, phe
10 Various Aspartic acid/asparagi
11 Medium-chain acylcarnitines C8:1, C10:3
12 Various C22, NEFA
Hbut, b-Hydroxybutyrate; (), negative factor load for this metabolite on this factor; NEF
The Journal of Thoracic and Cachain acylcarnitines (HR, 1.20; 95% CI, 1.06–1.35;
P ¼ .004).
After multivariate adjustment for the clinical variables
and significant factors on univariate analyses, these 3 fac-
tors remained significantly associated with the risk of
adverse events: factor 2 (HR, 1.23; 95% CI, 1.10–1.38;
P < .001); factor 5 (HR, 1.17; 95% CI, 1.01–1.37;
P ¼ .04); factor 6 (HR, 1.14; 95% CI, 1.02–1.27;
P ¼ .03; Table 4). The clinical variables, ejection fraction
(P ¼ .05) and preprocedure heparin use (P ¼ .06), were
also retained in the final model. Kaplan-Meier curves
demonstrating the relationship between factor 2 levels and
adverse outcomes after CABG are presented in Figure 1,
showing a linear relation between metabolite factor levels
and outcomes, with greater metabolite factor levels
associated with a greater probability of adverse events.ividual components Eigenvalue Variance
OH/C8-DC, C12, C12:1, C14, C14:1,
C, C14:2, C16:1, C16:1-OH/C14:1-DC,
16:1-DC
15.69 0.26
C, C6-DC, C6:1-DC/C8:1-OH, C8:1,
10:2, C10:3, C10-OH/C8-DC,
itrulline
5.72 0.09
4-OH/C12-DC, C16-OH/C14-DC,
18:1-OH/C16:1-DC,
C, C20-OH/C18-DC, C20
4.41 0.07
-DC, C18,C18:1, C18:2, C20:4 3.17 0.05
, C2, alanine() 2.83 0.05
2.52 0.04
line, phenylalanine, ornithine 2.25 0.04
stidine, citrulline 1.90 0.03
nylalanine, C5:1 1.74 0.03
ne, C5:1(), C5-OH/C3-DC 1.49 0.02
1.27 0.02
1.11 0.02
A, nonesterified fatty acids.
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TABLE 3. Relationship between metabolite factor levels and adverse events
Factor Term
Factor levels
HR (95% CI) P value*No event subjects (n ¼ 352) Event subjects (n ¼ 126)
1 Medium-chain acylcarnitines 0.02  1.1 0.06  0.74 1.07 (0.94–1.23) .30
2 Short-chain dicarboxyl-acylcarnitinesy 0.09  0.85 0.24  1.3 1.19 (1.07–1.33) .001
3 Long-chain dicarboxyl-acylcarnitines 0.04  0.81 0.12  1.39 1.11 (0.99–1.24) .08
4 Long-chain acylcarnitines 0.03  1.00 0.09  0.99 0.90 (0.75–1.08) .25
5 Ketone-relatedy 0.07  0.92 0.19  1.17 1.21 (1.04–1.41) .02
6 Short-chain acylcarnitinesy 0.07  0.71 0.19  1.52 1.20 (1.06–1.35) .004
7 Branched-chain amino acids 0.01  0.98 0.03  1.06 1.02 (0.85–1.21) .87
8 Urea cycle amino acids 0.03  0.97 0.09  1.08 0.91 (0.72–1.13) .39
9 Amino acids 0.001  1.01 0.002  0.98 1.15 (0.96–1.38) .13
10 Various 0.04  0.99 0.10  1.03 1.02 (0.86–1.20) .86
11 Medium-chain acylcarnitines 0.05  0.95 0.14  1.12 1.16 (0.99–1.37) .07
12 Various 0.02  0.98 0.05  1.05 1.07 (0.90–1.27) .48
HR, Hazard ratio; CI, confidence interval. *P value for univariate Cox proportional hazards regression model of association of factor level with time-to-event. yMetabolite factors
significantly associated with time-to-event.
Acquired Cardiovascular Disease Shah et al
A
C
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factors 5 and 6 with adverse event are presented in
Figures 2 and 3.DISCUSSION
To our knowledge, this is the first report of an association
between the baseline plasma metabolic profiles and out-
comes after CABG. In this cohort, elevated levels of
short-chain dicarboxylacylcarnitines, ketone-related me-
tabolites, and short-chain acylcarnitines were predictive of
a composite endpoint of MI, repeat revascularization, or
death at any point after CABG. This predictive capacity
held true after adjustment for numerous clinical covariates
known to be associated with cardiovascular events.
Our group has previously observed that elevated levels of
short-chain dicarboxylacylcarnitines are independently
associated with a greater risk of death and incident MI for
those undergoing cardiac catheterization.7,14 Additionally,
we have previously shown that adding the metabolic
profiles to the clinical risk assessment tools can
significantly improve risk stratification and help reclassify
patients with intermediate-risk coronary artery disease.7
The results of the present study have extended those find-
ings into this specific subgroup of patients with coronary
artery disease who experience adverse events afterTABLE 4. Multivariate model for time to adverse event
Variable HR (95% CI) Adjusted P value*
Factor 2 1.23 (1.10–1.38) <.001
Factor 5 1.17 (1.01–1.37) .04
Factor 6 1.14 (1.02–1.27) .03
Ejection fraction 0.99 (0.98–1.00) .05
Preprocedure heparin use 1.43 (0.98–2.10) .06
HR, Hazard ratio; CI, confidence interval. *Adjusted for age, sex, race, hyperlipid-
emia, diabetes, renal disease, smoking, body mass index, ejection fraction, number
of diseased coronary vessels, preprocedural heparin use, and factors significant on
univariate analyses (factors 2, 5, and 6).
876 The Journal of Thoracic and Cardiovascular SurgCABG, patients with a more severe disease burden in
a group with a more homogeneous degree of coronary
artery disease severity.
Dicarboxylated acylcarnitines can be derived by u-oxi-
dation of fatty acids by way of microsomal cytochrome
p450 enzymes. Long-chain dicarboxylated fatty acyl
coenzyme A (CoA) is shortened mainly by peroxisomal
oxidation15 and, when converted to the cognate acylcarni-
tines, is diagnostic for several inborn errors of metabo-
lism.16 Hence, factor 2 might reflect changes in flux
through the microsomal cytochrome p450 and/or peroxi-
somal oxidation systems. However, dicarboxylated acylcar-
nitines can also be derived from CoA esters generated
during oxidation of amino acids or other metabolic fuels
in the mitochondria. Thus, the pathways by which these
metabolites are generated and their biologic significance
remain to be investigated.FIGURE 1. Kaplan-Meier curve for relationship between factor 2 levels
and adverse events showing adjusted Kaplan-Meier curve of relationship
between tertiles of metabolite factor 2 and event-free survival after coro-
nary artery bypass grafting (CABG), adjusted for all variables retained in
final multivariate model, demonstrating linear relationship between factor
2 levels and decreased event-free survival.MI, Myocardial infarction; PCI,
percutaneous coronary intervention.
ery c April 2012
FIGURE 2. Kaplan-Meier curve for relationship between factor 5 levels
and adverse events showing adjusted Kaplan-Meier curve of relationship
between tertiles of metabolite factor 5 and event-free survival after coro-
nary artery bypass grafting (CABG), adjusted for all variables retained in
final multivariate model, demonstrating linear relationship between factor
5 levels and decreased event-free survival.MI, Myocardial infarction; PCI,
percutaneous coronary intervention.
FIGURE 3. Kaplan-Meier curve for relationship between factor 6 levels
and adverse events showing adjusted Kaplan-Meier curve of relationship
between tertiles of metabolite factor 6 and event-free survival after coro-
nary artery bypass grafting (CABG), adjusted for all variables retained in
final multivariate model, demonstrating linear relationship between factor
6 levels and decreased event-free survival.MI, Myocardial infarction; PCI,
percutaneous coronary intervention.
Shah et al Acquired Cardiovascular Disease
A
C
DShort chain acylcarnitines (factor 6) are also products of
fatty acid oxidation. Similar to dicarboxylacylcarnitines,
elevated systemic levels of short chain acylcarnitines can
be indicative of inborn errors of metabolism. For example,
butyrylcarnitine is elevated in patients with short-chain
acyl-CoA dehydrogenase deficiency. The elevated levels
of factor 6 in our adverse event population could also
have be related to errors in fatty acid oxidation.
In addition to acylcarnitines, a group of ketone-related
metabolites were predictive of adverse outcomes in our
study. During normal conditions, the heart preferentially
oxidizes fatty acids for energy. However, during periods
of metabolic stress, such as during an ischemic event,
glucose becomes the predominant source of fuel, which is
protective.17,18 Failure of a cell to increase glucose uptake
can result in cellular dysfunction.19 Increased levels of
ketones (1) correlate with the level of cardiac dysfunction20;
(2) increase reactive oxygen species production17; and (3)
decrease glucose uptake.17 These mechanisms could
explain the increased levels of ketone-related metabolites
in patients experiencing adverse events after CABG.
There are potential implications of these findings. First,
with respect to clinical applicability, our results suggest
that the metabolic profiling of patients undergoing CABG
could provide healthcare providers an additional tool for
identifying patients at greater risk of adverse events, facili-
tating personalized tailoring of the revascularization and
postprocedure treatment of these patients. For example,
patients with greater preoperative plasma levels of short-
chain dicarboxylacylcarnitines could benefit from total
arterial revascularization, postoperative clopidogrel useThe Journal of Thoracic and Ca(instead of aspirin), and closer postdischarge follow-up.
Although we are optimistic about such a role of these novel
biomarkers, such applications necessitate additional stud-
ies, including further validation and prospective outcome
studies. Second, specific metabolites and metabolic path-
ways might provide insight into novel mechanisms of
disease in patients who experience adverse events after
CABG. We have previously observed that metabolic pro-
files are heritable,12 and genetic variation has been shown
to be associated with metabolic traits21; thus, the identified
metabolic profiles might actually be reporting on underly-
ing genetic variations that increase the risk of adverse events
after CABG. Both of these implications provide fertile
opportunity for additional study.
The limitations of the present study are worth noting.
First, although blood was drawn from all study subjects
before CABG, potential variability existed in the clinical
states of these patients at sampling. For example, patients
experiencing non–ST-segment elevation myocardial infarc-
tion might have different metabolite profiles than patients
undergoing elective cardiac catheterization. However, we
did adjust for preprocedural heparin use as a surrogate,
because most patients with non–ST-segment elevation
myocardial infarction would be treated with heparin before
cardiac catheterization. Second, although mass spectrome-
try is a readily available technology, the quantification of
the plasma concentrations of these metabolites involved
the use of a specialized center experienced in performing
these assays. Many clinical laboratories might not have
the capabilities to perform these assays in a timely fashion
at present. Work is ongoing to translate these findings
into more readily available clinical tools, includingrdiovascular Surgery c Volume 143, Number 4 877
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profiles preoperatively. Other limitations included the bias
of not having enrolled unstable patients who were unable
to undergo the consent process because of their instability
(ie, ST-segment elevation MI), and the nonrandomized se-
lection of patients.
In conclusion, we have identified metabolic profiles com-
posed of short-chain dicarboxylacylcarnitines, ketone-
related metabolites, and short-chain acylcarnitines that
predict adverse outcomes after CABG independent of stan-
dard clinical predictors of risk. These findings suggest that
metabolites could be significant cardiovascular risk bio-
markers that might shed light on novel biochemical path-
ways of disease and supplement clinical risk assessment
models in patients undergoing CABG.
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